Zydus launches India’s first trivalent flu vax

New Delhi: Zydus Lifesciences on Tuesday launched India’s first trivalent influenza vaccine, aligning with the global recommendations of the World Health Organization (WHO).

Seasonal influenza viruses evolve rapidly, necessitating annual updates to vaccine compositions. The WHO, thus, recommended trivalent vaccines for use in the 2025-2026 Northern Hemisphere (NH) influenza season.

The new Vaxiflu-Trivalent Influenza Vaccine (TIV) is recommended for individuals aged 6 months and above. It will effectively protect strains such as an A/Victoria/4897/2022 (H1N1) pdm09-like virus; an A/Croatia/10136RV/2023 (H3N2)-like virus; and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus, stated the company.

Globally, the influenza vaccine is available as quadrivalent and trivalent formulations. India earlier followed a quadrivalent flu vaccine regimen, which offered protection against these strains, as well as the influenza B Yamagata virus.